Does This News From the FDA Make Eli Lilly a Buy for 2025?
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark.
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...
Zacks.com on MSN4d
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
The Motley Fool on MSN1d
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Earlier this month, Lilly released results from a clinical trial in which the company compared Zepbound directly against ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
GlobalData on MSN4d
FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea
Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive ...
BioSpace4d
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...